Drug intelligence / Profile preview

eluxadoline

Development stage
Approved
Lead developer
Allergan
Modality
Small Molecules
Administration
Oral
01

Overview

Eluxadoline is a small molecule medication used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults. It acts as a mixed mu-opioid receptor agonist and kappa-opioid receptor agonist, and as a delta-opioid receptor antagonist. Its primary mechanism involves reducing intestinal contractility and normalizing stress-induced acceleration of upper gastrointestinal transit. This results in decreased bowel activity and improved symptoms of abdominal pain and diarrhea[2][10][7]. Eluxadoline is available only by prescription.

Brand names
ViberziTruberzi
Other names
5-({(4-carbamoyl-2,6-dimethyl-L-phenylalanyl)[(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino}methyl)-2-methoxybenzoic acid
02

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)

Beyond the preview

Go deeper on eluxadoline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on eluxadoline.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call